Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 11.63% is 339% above its 5-year average of -4.86%, near the high end of its 5-year range (-513.23%–47.78%).
5.95% below its 12-month average of 12.37%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 11.36%.
EBITDA MARGIN
11.63%
EBITDA MARGIN AVG TTM
12.37%
EBITDA MARGIN AVG 3Y
0.83%
EBITDA MARGIN AVG 5Y
-4.86%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-5.95%
CURRENT VS 3Y AVG
+1295.32%
CURRENT VS 5Y AVG
+339.30%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Kiniksa Pharmaceuticals International, plc
Market Cap
$5.87B
EBITDA Margin
11.63%
TTM Avg
12.37%
3Y Avg
0.83%
5Y Avg
-4.86%
Market Cap
$5.89B
EBITDA Margin
-256.72%
TTM Avg
-936.95%
3Y Avg
-3212.66%
5Y Avg
-4222.05%
Market Cap
$5.95B
EBITDA Margin
30.20%
TTM Avg
18.88%
3Y Avg
24.58%
5Y Avg
33.74%
Market Cap
$5.79B
EBITDA Margin
-139.44%
TTM Avg
-176.89%
3Y Avg
-12100.88%
5Y Avg
-12100.88%
Market Cap
$5.61B
EBITDA Margin
-4686.36%
TTM Avg
-7375.40%
3Y Avg
-15092.23%
5Y Avg
-12098.10%
Market Cap
$6.23B
EBITDA Margin
-100.49%
TTM Avg
-151.66%
3Y Avg
-322.50%
5Y Avg
-1329.03%
Market Cap
$5.52B
EBITDA Margin
1.58%
TTM Avg
-0.29%
3Y Avg
0.97%
5Y Avg
0.97%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals International, plc (KNSA) | $5.87B | 11.63% | 12.37% | 0.83% | -4.86% |
| GRAIL Inc. (GRAL)vs › | $5.89B | -256.72% | -936.95% | -3212.66% | -4222.05% |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.95B | 30.20% | 18.88% | 24.58% | 33.74% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.79B | -139.44% | -176.89% | -12100.88% | -12100.88% |
| Kodiak Sciences Inc. (KOD)vs › | $5.78B | N/A | N/A | N/A | N/A |
| CG Oncology Inc. (CGON)vs › | $5.61B | -4686.36% | -7375.40% | -15092.23% | -12098.10% |
| RadNet, Inc. (RDNT)vs › | $5.53B | 11.91% | 12.58% | 14.79% | 16.03% |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.23B | -100.49% | -151.66% | -322.50% | -1329.03% |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.52B | 1.58% | -0.29% | 0.97% | 0.97% |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.32B | 51.73% | 11.80% | -10.91% | -33.87% |
Gross Margin
54.5%
EBITDA Margin
11.6%
Operating Margin
11.9%
Net Margin
9.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 11.36% |
| 2026-03-31 | 13.88% |
| 2025-12-31 | 10.01% |
| 2025-09-30 | 13.49% |
| 2025-06-30 | 13.09% |
| 2025-03-31 | 9.88% |
| 2024-12-31 | -15.42% |
| 2024-09-30 | -8.25% |
| 2024-06-30 | 0.29% |
| 2024-03-31 | -20.13% |
| 2023-12-31 | 0.38% |
| 2023-09-30 | -14.81% |
| 2023-06-30 | -2.93% |
| 2023-03-31 | -20.82% |
| 2022-12-31 | 11.52% |
| 2022-09-30 | 47.78% |
| 2022-06-30 | -67.74% |
| 2022-03-31 | -69.05% |
| 2021-12-31 | -189.19% |
| 2021-09-30 | -244.66% |
| 2021-06-30 | -513.23% |
